Chicago, Illinois — According to state and local economic development sources Exicure plans to invest $2,000,000.00 to build out new space in Chicago. The company plans to occupy the new space at 2430 N Halsted St in Chicago, on or about January 1, 2021. According to the company website Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology. SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

To learn more about Exicure, visit http://www.exicuretx.com/

Company Contact:
David Giljohann, Chief Executive Officer
https://www.linkedin.com/in/david-giljohann-39029b24/
847-673-1700

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved